MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paris, H.
Right arrow Articles by Senard, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paris, H.
Right arrow Articles by Senard, J. M.

Interactions of full and partial agonists with HT29 cell alpha 2- adrenoceptor: comparative study of [3H]UK-14,304 and [3H]clonidine binding

H Paris, J Galitzky and JM Senard

INSERM U-317, Institut de Physiologie, Universite Paul Sabatier, Toulouse, France.

The HT29 cell line expresses alpha 2-adrenoceptors that are negatively coupled to the adenylate cyclase system and is, in this respect, a valuable model for in vitro study of alpha 2-adrenergic receptivity in a tissue from human origin. In these cancerous cells, UK-14,304 is a full agonist of the alpha 2-adrenergic-mediated inhibition of the vasoactive intestinal peptide-induced cyclic AMP accumulation, whereas clonidine acts only as a partial agonist. In the present report, we used [3H]UK-14,304 as radioligand and compared its binding characteristics with those of [3H]clonidine in order to better understand the difference between full and partial agonism on the basis of agonist/receptor interactions. [3H]UK-14,304 labeled with high affinity (KD = 0.39 +/- 0.05 nM) a single class of sites having the pharmacological specificity of an alpha 2-adrenoceptor. Comparison of [3H]UK-14,304, [3H]clonidine, and [3H]yohimbine Bmax proved that both 3H-agonists labeled the same number of sites (172 +/- 14 versus 179 +/- 21 fmol/mg of protein), whereas the 3H-antagonist recognized more sites (246 +/- 22 fmol/mg of protein). Inhibition of [3H]yohimbine by the two agonists was consistent with the existence of an heterogeneous population of receptors and analysis of the data according a two-site inhibition model showed 1) that the KiL/KiH ratio was higher for UK- 14,304 than for clonidine and 2) that the percentages of high affinity state receptor recognized by both agonists were identical (56 +/- 4% with UK-14,304 and 59 +/- 5% with clonidine). Kinetics of [3H]UK-14,304 and [3H]clonidine binding indicated more complex agonist-receptor interactions than equilibrium data did. Association as well as dissociation of both radioligands appeared to be biphasic, suggesting a relative heterogeneity of 3H-agonist binding sites. Kinetic behavior of [3H]UK-14,304 only differed from that of [3H]clonidine by a much slower dissociation rate and by its ability to induce the formation of a tightly bound component, which corresponded to the formation of a very stable full agonist/receptor/Gi complex. Effects of guanosine-5'- (imido)-triphosphate and GTP on [3H]UK-14,304 and [3H]clonidine binding also proved that the agonists were not similarly sensitive to guanine nucleotides.

Volume 35, Issue 3, pp. 345-354, 03/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
HypertensionHome page
E. K. Jackson, D. G. Gillespie, C. Zhu, J. Ren, L. C. Zacharia, and Z. Mi
{alpha}2-Adrenoceptors Enhance Angiotensin II-Induced Renal Vasoconstriction: Role for NADPH Oxidase and RhoA
Hypertension, March 1, 2008; 51(3): 719 - 726.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. K. Jackson, L. Gao, and C. Zhu
Mechanism of the Vascular Angiotensin II/{alpha}2-Adrenoceptor Interaction
J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1109 - 1116.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
T. Adachi, D. M. Robinson, G. B. Miles, and G. D. Funk
Noradrenergic modulation of XII motoneuron inspiratory activity does not involve {alpha}2-receptor inhibition of the Ih current or presynaptic glutamate release
J Appl Physiol, April 1, 2005; 98(4): 1297 - 1308.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. K. Jackson, W. A. Herzer, C. K. Kost Jr, and S. J. Vyas
Enhanced Interaction Between Renovascular {alpha}2-Adrenoceptors and Angiotensin II Receptors in Genetic Hypertension
Hypertension, September 1, 2001; 38(3): 353 - 360.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
W.-N. Tian, D. D. Miller, and R. C. Deth
Bidirectional Allosteric Effects of Agonists and GTP at alpha 2A/D-Adrenoceptors
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 664 - 671.
[Abstract] [Full Text]


Home page
J. Neurophysiol.Home page
D. H. Lee, X. Liu, H. T. Kim, K. Chung, and J. M. Chung
Receptor Subtype Mediating the Adrenergic Sensitivity of Pain Behavior and Ectopic Discharges in Neuropathic Lewis Rats
J Neurophysiol, May 1, 1999; 81(5): 2226 - 2233.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Nasman, C. C. Jansson, and K. E.O. Akerman
The Second Intracellular Loop of the alpha 2-Adrenergic Receptors Determines Subtype-specific Coupling to cAMP Production
J. Biol. Chem., April 11, 1997; 272(15): 9703 - 9708.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1989 by the American Society for Pharmacology and Experimental Therapeutics